[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2023004188A - Phospholipid compounds and uses thereof. - Google Patents

Phospholipid compounds and uses thereof.

Info

Publication number
MX2023004188A
MX2023004188A MX2023004188A MX2023004188A MX2023004188A MX 2023004188 A MX2023004188 A MX 2023004188A MX 2023004188 A MX2023004188 A MX 2023004188A MX 2023004188 A MX2023004188 A MX 2023004188A MX 2023004188 A MX2023004188 A MX 2023004188A
Authority
MX
Mexico
Prior art keywords
compounds
phospholipid compounds
phospholipid
alone
treatment
Prior art date
Application number
MX2023004188A
Other languages
Spanish (es)
Inventor
Peiyuan Wang
Scott E Lazerwith
Jonathan William Medley
Philip A Morganelli
Thomas P Stratton
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2023004188A publication Critical patent/MX2023004188A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compounds and methods of using said compounds, alone or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
MX2023004188A 2020-10-16 2021-10-15 Phospholipid compounds and uses thereof. MX2023004188A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063093037P 2020-10-16 2020-10-16
US202163151456P 2021-02-19 2021-02-19
PCT/US2021/055183 WO2022081973A1 (en) 2020-10-16 2021-10-15 Phospholipid compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2023004188A true MX2023004188A (en) 2023-05-03

Family

ID=78536645

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004188A MX2023004188A (en) 2020-10-16 2021-10-15 Phospholipid compounds and uses thereof.

Country Status (16)

Country Link
US (2) US20220143052A1 (en)
EP (1) EP4228685A1 (en)
JP (2) JP2023547599A (en)
KR (1) KR20230088432A (en)
CN (1) CN116322759A (en)
AU (1) AU2021361059A1 (en)
CA (1) CA3193879A1 (en)
CL (2) CL2023001062A1 (en)
CO (1) CO2023004594A2 (en)
CR (1) CR20230164A (en)
DO (1) DOP2023000074A (en)
IL (1) IL301809A (en)
MX (1) MX2023004188A (en)
PE (1) PE20230858A1 (en)
TW (2) TWI811812B (en)
WO (1) WO2022081973A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021312946A1 (en) * 2020-07-24 2023-03-09 The Regents Of The University Of California Antiviral prodrugs, pharmaceutical formulations, and methods
WO2022046631A1 (en) 2020-08-24 2022-03-03 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
TWI811812B (en) 2020-10-16 2023-08-11 美商基利科學股份有限公司 Phospholipid compounds and uses thereof
EP4387977A1 (en) 2021-08-18 2024-06-26 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN114903897B (en) * 2022-04-27 2024-02-13 中国人民解放军海军军医大学 Application of stephanine in preparation of anti-tick-borne encephalitis virus medicament

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
EP0262876B1 (en) 1986-09-27 1992-04-29 Toyo Jozo Kabushiki Kaisha Nucleoside-phospholipid conjugate
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
CN1414854B (en) 1999-12-03 2015-08-19 加利福尼亚大学圣地亚哥分校董事会 Phosphonate compound
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
DE60105424T2 (en) 2000-05-26 2005-09-22 Idenix (Cayman) Ltd. METHODS FOR TREATING DELTA HEPATITIS VIRUS INFECTIONS WITH BETA-L-2 'DEOXY NUCLEOSIDES
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
NZ544671A (en) 2003-06-26 2009-02-28 Biotron Ltd Antiviral compounds and methods
WO2006066074A2 (en) 2004-12-16 2006-06-22 The Regents Of The University Of California Lung-targeted drugs
US20090156545A1 (en) 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
NZ564398A (en) 2005-06-24 2011-11-25 Biotron Ltd 2-Naphthoyl-guanidine derivatives as antiviral agents
KR101558403B1 (en) 2007-08-03 2015-10-07 바이오트론 리미티드 Hepatitis c antiviral compositions and methods
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
EP2342616A2 (en) 2008-09-23 2011-07-13 Alnylam Pharmaceuticals Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
ES2534044T3 (en) 2008-11-06 2015-04-16 Vascular Biogenics Ltd. Oxidized lipid compounds and uses thereof
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
CA2860289C (en) 2011-12-22 2021-03-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections
CN104603125A (en) 2012-09-10 2015-05-06 弗·哈夫曼-拉罗切有限公司 6-amino acid heteroaryldihydropyrimidines for treatment and prophylaxis of hepatitis b virus infection
ES2865402T3 (en) 2012-12-21 2021-10-15 Janssen Biopharma Inc 4'-fluoronucleosides, 4'-fluoronucleotides and analogues thereof for the treatment of HCV
EP3401320B1 (en) 2013-03-15 2020-05-13 The Regents of the University of California Acyclic nucleoside phosphonate diesters for use in treating human papilloma virus, cervical intraepithelial neoplasia, anal intraepithelial neoplasia, or vulvar intraepithelial neoplasia
CA2913206C (en) 2013-06-26 2022-08-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
PL3043865T3 (en) 2013-09-11 2021-07-05 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
CN105829333A (en) 2013-10-11 2016-08-03 艾丽奥斯生物制药有限公司 Substituted nucleosides, nucleotides and analogs thereof
SG11201605970QA (en) 2014-01-30 2016-08-30 Hoffmann La Roche Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
ES2714110T3 (en) 2014-03-07 2019-05-27 Hoffmann La Roche Novel 6-fused heteroaryl dihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
CN106459032B (en) 2014-05-13 2019-04-05 豪夫迈·罗氏有限公司 Treat and prevent hepatitis b virus infected new dihydro Quinolizinone type
SI3160476T1 (en) 2014-06-24 2021-05-31 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof for use in the treatment of viral infection
CN106604734B (en) 2014-06-24 2021-08-13 艾丽奥斯生物制药有限公司 Substituted nucleosides, nucleotides and analogs thereof
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
EP3180319B1 (en) 2014-08-14 2018-10-03 F.Hoffmann-La Roche Ag Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
AR103222A1 (en) 2014-12-23 2017-04-26 Hoffmann La Roche PROCEDURE FOR THE PREPARATION OF ANALOGS OF 4-PHENYL-5-ALCOXICARBONIL-2-THIAZOL-2-IL-1,4-DIHYDROPIRIMIDINE
WO2016107832A1 (en) 2014-12-30 2016-07-07 F. Hoffmann-La Roche Ag Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
EP3240913A1 (en) 2014-12-31 2017-11-08 F. Hoffmann-La Roche AG A novel high-throughput method for quantification of hbv cccdna from cell lysate by real-time pcr
MA41338B1 (en) 2015-01-16 2019-07-31 Hoffmann La Roche Pyrazine compounds for the treatment of infectious diseases
EP3250685A1 (en) 2015-01-27 2017-12-06 F. Hoffmann-La Roche AG Recombinant hbv cccdna, the method to generate thereof and the use thereof
EP3256471B1 (en) 2015-02-11 2018-12-12 F. Hoffmann-La Roche AG Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
US11963972B2 (en) 2016-03-23 2024-04-23 Emory University Antiviral agents and nucleoside analogs for treatment of Zika virus
ES2910136T3 (en) 2017-02-08 2022-05-11 Biotron Ltd Flu treatment methods
JP6824434B2 (en) 2017-03-14 2021-02-03 ギリアード サイエンシーズ， インコーポレイテッド How to treat feline coronavirus infection
CN111491634A (en) 2017-07-31 2020-08-04 詹纽瑞治疗公司 Organic phosphate derivatives
CR20200126A (en) 2017-09-18 2020-07-11 Janssen Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
MX2020006864A (en) 2017-12-27 2020-11-11 Univ Emory Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents.
SG11202008346PA (en) 2018-03-02 2020-09-29 January Therapeutics Inc Nanoparticle compositions
TW202315607A (en) 2020-02-18 2023-04-16 美商基利科學股份有限公司 Antiviral compounds
CN113292565B (en) 2020-02-24 2023-01-31 浙江森科建设有限公司 Nucleoside compound and preparation method and application thereof
CN111233929B (en) 2020-02-28 2023-02-28 成都阿奇生物医药科技有限公司 Deuterated nucleoside analogue and preparation method and application thereof
CN111393243B (en) 2020-04-22 2022-12-13 深圳市宝安区新材料研究院 Synthesis method of phosphorus chiral nucleoside drug and drug obtained by method
AU2021312946A1 (en) 2020-07-24 2023-03-09 The Regents Of The University Of California Antiviral prodrugs, pharmaceutical formulations, and methods
WO2022046631A1 (en) 2020-08-24 2022-03-03 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
CN112010916B (en) 2020-09-09 2022-12-27 广东东阳光药业有限公司 Phosphoramidate derivatives of nucleoside compounds and uses thereof
TWI811812B (en) 2020-10-16 2023-08-11 美商基利科學股份有限公司 Phospholipid compounds and uses thereof
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
CN112645982B (en) 2020-12-22 2023-04-07 苏州正济药业有限公司 Preparation and purification method of key intermediate of Rudexiluwei
US11795159B2 (en) 2021-05-26 2023-10-24 Purdue Research Foundation Compounds for the treatment of SARS
US11834408B2 (en) 2021-05-28 2023-12-05 Purdue Research Foundation Compounds for the treatment of SARS
TW202317144A (en) 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 Orally-bioavailable nucleoside analogs
CN115475171A (en) 2021-06-16 2022-12-16 中国医学科学院医药生物技术研究所 Compound with anti-coronavirus activity and application thereof
JPWO2022270478A1 (en) 2021-06-21 2022-12-29
CN115504940A (en) 2021-06-23 2022-12-23 中国科学院上海药物研究所 Amide compound, preparation method and pharmaceutical application thereof
WO2022268111A1 (en) 2021-06-25 2022-12-29 前沿生物药业(南京)股份有限公司 Antiviral pharmaceutical composition, and preparation method therefor and application thereof
KR20230001595A (en) 2021-06-28 2023-01-05 재단법인 대구경북첨단의료산업진흥재단 An antiviral agent comprising a triazinoindole derivative as an effective ingredient
US20240293384A1 (en) 2021-06-29 2024-09-05 The Regents Of The University Of California Methods and compositions for treatment of covid-19
WO2023272571A1 (en) 2021-06-30 2023-01-05 中国人民解放军军事科学院军事医学研究院 Medical use of 2,3-epoxy succinyl derivative
EP4366717A1 (en) 2021-07-08 2024-05-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Broad-spectrum antiviral drugs
MX2024000299A (en) 2021-07-09 2024-03-14 Aligos Therapeutics Inc Anti-viral compounds.
WO2023283831A1 (en) 2021-07-14 2023-01-19 上海药明康德新药开发有限公司 Virus main protease inhibitor, preparation method therefor, and use
JPWO2023286844A1 (en) 2021-07-15 2023-01-19
EP4119145A1 (en) 2021-07-15 2023-01-18 Dompe' Farmaceutici S.P.A. Compounds for the treatment of covid-19
TW202321210A (en) 2021-07-22 2023-06-01 瑞士商諾華公司 Compounds and compositions for the treatment of coronaviral related diseases
WO2023003610A1 (en) 2021-07-23 2023-01-26 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
KR20230018351A (en) 2021-07-29 2023-02-07 가톨릭대학교 산학협력단 Composition for the treatment of autoimmune rheumatic diseases through combination administration of remdesivir and immunomodulators
WO2023009187A1 (en) 2021-07-29 2023-02-02 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
WO2023008530A1 (en) 2021-07-30 2023-02-02 富士フイルム富山化学株式会社 Therapeutic agent for covid-19
WO2023011443A1 (en) 2021-08-02 2023-02-09 北京华益健康药物研究中心 3cl protease small-molecule inhibitor for treating or preventing coronavirus infection, and use thereof
MX2024001540A (en) 2021-08-03 2024-06-12 Cocrystal Pharma Inc Inhibitors for coronaviruses.
EP4130001A1 (en) 2021-08-03 2023-02-08 Studiengesellschaft Kohle mbH Process for the direct catalytic glycosylation of arenes
CA3226836A1 (en) 2021-08-06 2023-02-09 Intervet International B.V. Method of treating veterinary viral diseases
CN115703796A (en) 2021-08-09 2023-02-17 苏州恩泰新材料科技有限公司 Preparation method of important intermediate of Reidesciclovir
JP2023026155A (en) 2021-08-13 2023-02-24 国立研究開発法人理化学研究所 Anti-infective agent
WO2023039330A2 (en) 2021-08-17 2023-03-16 Southwest Research Institute Antiviral drugs targeting the n-terminal domain (ntd) of the coronavirus spike receptor binding domain (rbd)
EP4387625A1 (en) 2021-08-17 2024-06-26 Farahani, Ensieh Compounds for treatment of viral infections by neurotropic virus
WO2023023469A1 (en) 2021-08-17 2023-02-23 Southwest Research Institute Inhibitors for coronavirus
EP4387629A1 (en) 2021-08-18 2024-06-26 Katholieke Universiteit Leuven KU Leuven Research & Development 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues
WO2023023631A1 (en) 2021-08-18 2023-02-23 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
WO2023023651A1 (en) 2021-08-19 2023-02-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Quinacrine and derivatives thereof for treatment of viral infections
CN113648293B (en) 2021-08-19 2022-07-05 山东达因海洋生物制药股份有限公司 Application of p-benzoquinone and/or p-benzoquinone derivative in preparation of novel coronavirus resistant medicine
IL310854A (en) 2021-08-20 2024-04-01 Shionogi & Co Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action
JPWO2023022231A1 (en) 2021-08-20 2023-02-23
CN115716833A (en) 2021-08-26 2023-02-28 苏州旺山旺水生物医药有限公司 Preparation method of antiviral nucleoside analogue
CN117886870A (en) 2021-08-27 2024-04-16 南京知和医药科技有限公司 Novel cytidine derivative, and pharmaceutical composition and application thereof
US20230102656A1 (en) 2021-08-27 2023-03-30 Ut-Battelle, Llc Covalent inhibitors of coronavirus papain-like protease
TW202328093A (en) 2021-08-31 2023-07-16 美商帕迪斯生物科學公司 Crystalline inhibitors of cysteine proteases and methods of use thereof
CN115721661A (en) 2021-09-01 2023-03-03 常晓宇 Application of purine nucleoside medicament in preventing or treating coronavirus infectious diseases
CN115745960B (en) 2021-09-02 2024-08-30 中国科学院上海药物研究所 Compound containing quinolinone amide, preparation method, pharmaceutical composition and application thereof
CN115737665A (en) 2021-09-02 2023-03-07 广州谷森制药有限公司 Cytidine derivatives and antiviral uses related thereto
WO2023033098A1 (en) 2021-09-03 2023-03-09 塩野義製薬株式会社 Bicyclic nitrogen-containing heterocyclic derivative having virus growth inhibitory activity and pharmaceutical composition containing same
MX2024002885A (en) 2021-09-07 2024-04-22 Shanghai Qilu Pharmaceutical Res And Development Centre Ltd 3clpro protease inhibitor.
CN115594734B (en) 2021-09-09 2023-03-17 广东众生睿创生物科技有限公司 Ketoamide derivatives and their use
EP4148042A1 (en) 2021-09-10 2023-03-15 Centre National de la Recherche Scientifique Phenoxy-acetyl-thioureido-benzenesulfonamide derivatives, and their uses
WO2023043830A1 (en) 2021-09-15 2023-03-23 Clear Creek Bio, Inc. Combination therapies to treat viral infections
WO2023042879A1 (en) 2021-09-17 2023-03-23 塩野義製薬株式会社 Bicyclic heterocyclic derivative having viral growth inhibitory activity and pharmaceutical composition containing same
WO2023044462A1 (en) 2021-09-17 2023-03-23 Pardes Biosciences, Inc. Cysteine protease inhibitor formulations and method of use thereof
CN115819391A (en) 2021-09-17 2023-03-21 中国科学院上海药物研究所 Baicalein derivative, preparation method and application thereof
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
CN115554303B (en) 2021-09-18 2024-07-09 上海科技大学 Tricyclic compound, preparation method and application thereof
WO2023044171A1 (en) 2021-09-20 2023-03-23 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
WO2023048151A1 (en) 2021-09-22 2023-03-30 塩野義製薬株式会社 Cyclic peptide having virus proliferation inhibition activity
WO2023046900A1 (en) 2021-09-23 2023-03-30 Katholieke Universiteit Leuven Ribonucleoside analogues against -sars-cov-2
WO2023049643A1 (en) 2021-09-23 2023-03-30 City Of Hope Inhibitors of sars-cov-2
US20230108588A1 (en) 2021-09-27 2023-04-06 The Governors Of The University Of Alberta Rna virus inhibitor compounds and uses thereof
WO2023054292A1 (en) 2021-09-28 2023-04-06 塩野義製薬株式会社 Pharmaceutical composition containing triazine derivative
TW202330513A (en) 2021-09-28 2023-08-01 加拿大商愛彼特生物製藥公司 ) inhibitors and methods using same
WO2023054759A1 (en) 2021-09-30 2023-04-06 한국화학연구원 2-aminoquinazoline derivative and anti-viral composition comprising same
GB202114032D0 (en) 2021-09-30 2021-11-17 Univ Strathclyde Antivirals
CN117209555A (en) 2021-09-30 2023-12-12 中国科学院上海药物研究所 Cyano compound, preparation method and application thereof
EP4159721A1 (en) 2021-09-30 2023-04-05 Qubit Pharmaceuticals Condensed 3,3-difluoro-piperidine derivatives as inhibitors of coronaviruses 3-chymotrypsin-like protease
CN115894587A (en) 2021-09-30 2023-04-04 知和(山东)大药厂有限公司 Preparation of nucleoside derivative and application of nucleoside derivative in field of antiviral drugs
KR20230049329A (en) 2021-10-06 2023-04-13 (주)스파크바이오파마 Pyrimidodiazepine-based Compounds and Their Uses for Treating or Preventing Coronavirus Infection
TW202322799A (en) 2021-10-06 2023-06-16 美商Ｃ４醫藥公司 Coronavirus non-structural protein 3 degrading compounds
WO2023056936A1 (en) 2021-10-07 2023-04-13 南京知和医药科技有限公司 Nucleotide derivative, and pharmaceutical composition and use thereof
WO2023063884A2 (en) 2021-10-12 2023-04-20 Nanyang Technological University Generation of chiral sulfinate esters
EP4415823A1 (en) 2021-10-13 2024-08-21 Clear Creek Bio, Inc. Compounds and methods for treating coronaviruses
CN115710297A (en) 2021-10-20 2023-02-24 知和(山东)大药厂有限公司 Novel nucleotide derivatives, and pharmaceutical composition and application thereof
KR20240093977A (en) 2021-11-04 2024-06-24 선전 안티브이 파마 컴퍼니 리미티드 Crystalline form of isobutyrate nucleoside compound and method for producing the same
CN115806570B (en) 2021-11-15 2023-09-12 南京知和医药科技有限公司 Peptoid derivative, pharmaceutical composition and application thereof
KR20230119022A (en) 2021-11-24 2023-08-14 시오노기 앤드 컴파니, 리미티드 Formulations for oral administration containing triazine derivatives
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
CN115518058A (en) 2021-12-29 2022-12-27 河北医科大学 Application of N-cycloalkyl substituted aromatic methylamine compound in preparation of antiviral drug, structure and preparation method
US11760722B2 (en) 2022-01-18 2023-09-19 Ascletis Bioscience Co., Ltd. Inhibitors of cysteine proteases and methods of use thereof
WO2023054732A2 (en) 2022-01-19 2023-04-06 塩野義製薬株式会社 Pharmaceutical for treating novel coronavirus infection
CN116925040A (en) 2022-03-31 2023-10-24 陕西盘龙药业集团股份有限公司 PROTACs targeting coronavirus 3CL protease and preparation method and application thereof
CN115504964A (en) 2022-04-12 2022-12-23 海创药业股份有限公司 Deuterated heterocyclic ketone compound and application thereof
CN115650959B (en) 2022-05-20 2023-10-20 南京济群医药科技股份有限公司 Process for the preparation or purification of compounds
CN115636817B (en) 2022-06-20 2023-11-24 山东大学 Isatin derivative containing triazole ring, and preparation method and application thereof
CN115490681B (en) 2022-07-08 2023-04-18 歌礼生物科技（杭州）有限公司 Triazine derivatives
CN115572298B (en) 2022-07-22 2024-11-08 苏州旺山旺水生物医药股份有限公司 Crystal form, preparation method and application of nucleoside analogue and salt thereof
CN115466225A (en) 2022-08-16 2022-12-13 中国科学院上海药物研究所 Amide compound, preparation method, pharmaceutical composition and application thereof
CN115521208B (en) 2022-09-21 2023-09-01 天津科技大学 Novel coronavirus 3CL protease inhibitor and application
CN115521316B (en) 2022-09-23 2024-07-26 深圳安泰维生物医药有限公司 Preparation method of nucleoside compound or intermediate thereof and intermediate of nucleoside compound
CN115521337A (en) 2022-09-26 2022-12-27 南京康立瑞生物科技有限公司 Synthetic method of Reidesciclovir intermediate
CN115894498A (en) 2022-10-01 2023-04-04 海化生命(厦门)科技有限公司 Potential antiviral drug intermediate BL and synthetic method thereof
US11655255B2 (en) 2022-10-17 2023-05-23 Sph No.1 Biochemical & Pharmaceutical Co., Ltd. Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein
CN115894504A (en) 2022-10-21 2023-04-04 深圳信立泰药业股份有限公司 Coronavirus 3CL protease inhibitor and application thereof
CN115651022A (en) 2022-10-27 2023-01-31 南京康立瑞生物科技有限公司 Synthetic method of high-purity Reidesvir intermediate
CN115887471B (en) 2022-11-01 2024-02-13 南开大学 Application of adefovir in preparing medicine for treating skin fibrosis diseases
CN115894443B (en) 2022-11-17 2024-03-29 上海市重大传染病和生物安全研究院 Compound Ai Kuisi and application thereof
CN115504968B (en) 2022-11-21 2023-04-18 歌礼生物科技（杭州）有限公司 Triazine derivatives
CN115819423A (en) 2022-11-29 2023-03-21 武汉大学 ProTAC compound of Reidesciclovir or intermediate thereof, preparation method thereof and application of anti-EV 71
CN115850338A (en) 2022-12-12 2023-03-28 西安交通大学 Compound containing diazirine nucleosides as well as preparation method and application thereof
CN115947759A (en) 2022-12-13 2023-04-11 安徽大学 Preparation method of medicine Ruidexiwei for treating new coronary disease
CN115785080B (en) 2022-12-16 2024-10-11 陕西盘龙药业集团股份有限公司 Uracil parent nucleus compound and preparation method and application thereof

Also Published As

Publication number Publication date
KR20230088432A (en) 2023-06-19
AU2021361059A9 (en) 2024-08-01
TW202233203A (en) 2022-09-01
CR20230164A (en) 2023-06-23
WO2022081973A1 (en) 2022-04-21
JP2024111292A (en) 2024-08-16
US20230248753A1 (en) 2023-08-10
CL2024001186A1 (en) 2024-10-11
TW202344257A (en) 2023-11-16
TWI811812B (en) 2023-08-11
CO2023004594A2 (en) 2023-04-17
CA3193879A1 (en) 2022-04-21
US20220143052A1 (en) 2022-05-12
AU2021361059A1 (en) 2023-06-08
EP4228685A1 (en) 2023-08-23
IL301809A (en) 2023-05-01
CL2023001062A1 (en) 2023-11-10
US11963967B2 (en) 2024-04-23
DOP2023000074A (en) 2023-05-31
JP2023547599A (en) 2023-11-13
CN116322759A (en) 2023-06-23
PE20230858A1 (en) 2023-05-29

Similar Documents

Publication Publication Date Title
MX2023002195A (en) Compounds and methods for treatment of viral infections.
CR20230164A (en) Phospholipid compounds and uses thereof
CR20230100A (en) Phospholipid compounds and uses thereof
MX2022007930A (en) Diacylglycerol kinase modulating compounds.
MX2022015272A (en) Inhibitors of kras g12c protein and uses thereof.
MX2022016405A (en) 1'-cyano nucleoside analogs and uses thereof.
MX2024010591A (en) Compounds and methods for treatment of viral infections.
NO20064547L (en) Methods for treating HIV infection
SG10201902429PA (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2010002318A (en) 2,3-substituted azaindole derivatives for treating viral infections.
MX2009008617A (en) Use of il-23 antagonists for treatment of infection.
MX2021003773A (en) Pharmaceutical compositions comprising otic therapeutic agents and related methods.
EP4342473A3 (en) Compounds useful in hiv therapy
MX2022000712A (en) Nlrp3 modulators.
MX2021001612A (en) Compounds useful in hiv therapy.
ATE475408T1 (en) FORMULATIONS OF TIPIFARNIB FOR INTRAVENOUS ADMINISTRATION
MX2017013795A (en) Therapeutic combinations of antiviral and anti-inflammatory therapies.
BR112018014723A2 (en) bacterial ghosts for cancer treatment
WO2022063869A3 (en) Compounds for the treatment of viral infections
MX2022001261A (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases.
MX2022005388A (en) Pyrrolidine and piperidine compounds.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2018011095A (en) Carbapenem compounds.
MA40805A (en) LONG-ACTION PHARMACEUTICAL COMPOSITIONS AGAINST HEPATITIS C
MX2022001271A (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases.